Sub-micron affinity particles, grown inside engineered bacteria. Chromatography-free antibody purification, at scale.
Two technologies dominate antibody purification today, and both were engineered for a previous era of biomanufacturing. The economics, the footprint and the scaling profile no longer line up with where biologics demand is heading.
High-cost protein A resins. Pressure-limited packed columns with slow cycles, complex skids and heavy buffer consumption.
Single-use systems constrained by pressure and surface area. Scale comes through cassette multiplication rather than true process intensification.
Biologically manufactured affinity particles designed for fast-flow processing, lower infrastructure intensity, and scalable throughput.
Affinity nanoparticles self-assemble inside engineered bacteria. The protein A ligand is co-expressed and arrives already conjugated to the particle surface — no chemical coupling step, and endotoxin-free.
At 0.5–0.75 µm the particle exposes the binding chemistry on its outer surface. Antibodies bind without diffusing into a porous interior — the kinetic bottleneck of traditional resins disappears.
PHB is a biologically produced biopolymer formed directly inside engineered cells. The matrix is non-porous, with a carbon-neutral production pathway that avoids the multi-step synthetic manufacturing used in conventional affinity materials.
NanoSurface™ particles are produced by standard fermentation in engineered bacterial strains. The particles assemble inside the cell; harvest and lysis release them, already functionalised. No specialised manufacturing line, no synthetic resin chemistry, no chemical coupling step.
NanoFlo™ and NanoMag™ are the same nanoparticle deployed in two downstream workflows — continuous TFF capture and R&D workflows. Customisation extends the platform to bespoke ligand chemistries, customised for your process.
A suspension-format particle that pairs with standard tangential flow filtration to deliver chromatography-free capture. Direct integration with perfusion bioreactors; supports both batch and continuous mAb processing.
Superparamagnetic affinity beads with mechanical robustness for industrial use. A four-step protocol with magnetic clearance in three seconds — suitable for benchtop development through to high-throughput GMP.
Where NanoFlo™ sits against the two incumbent approaches to mAb capture, on the four metrics investors and process engineers actually weigh.
| ColumnsProtein A resin + skid | MembranesSingle-use cassettes | NanoFlo™Suspension over TFF | |
|---|---|---|---|
| Cost | High. Protein A resins + complex skids. | High. Single-use system economics. | 50%+ lower. Natural material, no coupling step. |
| Sustainability | Heavy water and buffer use. | Significant plastic waste. | Carbon-neutral PHB biopolymer. |
| Scalability | Hard to scale — pressure and compression limits. | Linear via added cassettes; constrained by pressure. | Input-based — adjust particle dose, not hardware. |
| Simplicity | Complex setup. Slow cycles. Column repacking. | Hardware + modules; easier than columns. | Drops into existing TFF. No specialised skids. |
NanoSurface™ removes synthetic resin manufacturing and chemical coupling, and lowers water and buffer load from the downstream process.
Fully organic PHB matrix produced through a carbon-neutral biological pathway rather than petroleum-derived synthesis.
Eliminates complex multi-step chemical synthesis in resin manufacturing.
Continuous capture over TFF reduces buffer consumption per gram of product captured.
Aligned with ESG-linked capital and the next decade of pharma sustainability reporting.
We are accepting a small number of process development teams into the NanoFlo™ alpha programme. The goal is concrete: validate the particle inside your own mAb capture workflow against your existing unit operations.
NanoSurface™ has been de-risked over two decades of academic and translational work. The 2026 Proto Axiom partnership puts the platform into a commercial vehicle for the first time.